Recent Updates
Recently added Catalysts
ENTA Positive Sentiment

EDP-938, A Respiratory Syncytial Virus Antiviral, Demonstrates a High Barrier to Resistance in a Human Challenge Study

Thursday, October 12, 2023 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: EDP-938, an antiviral for Respiratory Syncytial Virus (RSV), has shown a high barrier to resistance in a recent human challenge study. The results indicate that EDP-938 could be a promising treatment option for RSV, demonstrating effective antiviral properties. This development is significant for addressing RSV infections, particularly in vulnerable populations.
Price reaction · baseline $9.87 (2023-10-11 close) · hit pre-market · clean, no other ENTA news in the window
day 0 close · peak
-2.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • EDP-938 shows a high barrier to resistance against RSV.
  • The study demonstrates promising results in human trials.
  • Potential for EDP-938 to be a significant antiviral option.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~63 mo
Minimal dilution risk
Lead asset
EDP-235
Phase 2 · COVID-19

Full Press Release Details

• About About Us Management Team Board of Directors Timeline
• Pipeline Overview Hepatitis C Virus Respiratory Syncytial Virus SARS-CoV-2 Immunology KIT Inhibition STAT6 Inhibition MRGPRX2
• Science Overview Publications
• Patients Overview Clinical Trials Expanded Access Policy Resources
• Careers Join Us Culture Core Values Testimonials Benefits
• Collaborations Partnering
• Investors Overview Press Releases Events & Presentations Stock Information Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage Financials Quartlery Results Annual Reports SEC Filings Corporate Responsibility Overview Environmental Social Governance Investor Resources Investor FAQs RSS Feed 2026 Annual Meeting Email Alerts
• Contact Us
• About Us
• Management Team
• Board of Directors
• Timeline
• Overview
• Hepatitis C Virus
• Respiratory Syncytial Virus
• SARS-CoV-2
• Immunology KIT Inhibition STAT6 Inhibition MRGPRX2
• KIT Inhibition
• STAT6 Inhibition
• MRGPRX2
• Overview
• Publications
• Overview
• Clinical Trials
• Expanded Access Policy
• Resources
• Join Us
• Culture
• Core Values
• Testimonials
• Benefits
• Partnering
• Overview
• Press Releases
• Events & Presentations
• Stock Information Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage
• Financials Quartlery Results Annual Reports SEC Filings
• Corporate Responsibility Overview Environmental Social Governance
• Investor Resources Investor FAQs RSS Feed
• 2026 Annual Meeting
• Email Alerts
• Stock Quote & Chart
• Historic Price Lookup
• Investment Calculator
• Analyst Coverage
• Quartlery Results
• Annual Reports
• SEC Filings
• Overview
• Environmental
• Social
• Governance
• Investor FAQs
• RSS Feed
• Print Page Print Page
• Email Alerts Email Alerts
• RSS Feeds RSS Feeds
• Contact IR Contact IR

Frequently Asked Questions

What is EDP-938?

EDP-938 is an antiviral drug developed to treat Respiratory Syncytial Virus (RSV).

What did the human challenge study reveal?

The study demonstrated that EDP-938 has a high barrier to resistance against RSV.

Why is EDP-938 important?

EDP-938 could provide a significant treatment option for RSV, especially in vulnerable populations.

What is RSV?

Respiratory Syncytial Virus (RSV) is a common virus that causes respiratory infections, particularly in infants.

ShareAdd on Google
Tags: ENTA Viatris Investor Conferences Healthcare EDP-938 RSV antiviral human challenge study
Last updated: Oct 12, 2023

Biotech snapshot

Cash runway
$211M liquidity · $3M/mo burn
~63 mo
Minimal dilution risk
Lead asset
EDP-235Phase 2
COVID-19 →